Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Article

Open Access Gateway

Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study

Hauner Ha · Hastreiter L.a · Werdier D.b · Chen-Stute A.c · Scholze J.d · Blüher M.e

Author affiliations

aElse Kröner-Fresenius-Center for Nutritional Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; bSAM GmbH, Aachen, Germany; cAdipositas-Zentrum Oberhausen, Oberhausen, Germany; dCentrum für Innere Medizin, Medizinische Polyklinik, Charité-Universitätsmedizin, Berlin, Germany; eDepartment of Medicine, University of Leipzig, Leipzig, Germany

Corresponding Author

Prof. Dr. Hans Hauner

Else Kröner-Fresenius-Center for Nutritional Medicine

Klinikum rechts der Isar, Technische Universität München, Uptown Munich, Campus D

Georg-Brauchle-Ring 62, 80992 Munich, Germany

hans.hauner@tum.de

Related Articles for ""

Obes Facts 2017;10:407-419

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Abstract

Objective: To investigate the efficacy and safety of increasing doses of cathine (nor-pseudoephedrine) as a weight-lowering agent in patients with obesity. Methods: Overweight and obese patients (n = 241, mean BMI 34.6 ± 3.4 kg/m²) were randomly allocated to one of three doses of cathine (16 mg, 32 mg, 53.3 mg) or placebo in addition to a multimodal lifestyle intervention program in a multicenter, double-blind, controlled, dose-finding study for 24 weeks. Primary outcome was weight loss. Results: Treatment with the 3 doses of cathine resulted in a significantly greater weight loss compared to placebo over 24 weeks: 6.5 ± 4.2 kg for 16 mg cathine, 6.2 ± 4.7 kg for 32 mg cathine, and 9.1 ± 5.4 kg for 53.3 mg cathine versus 2.4 ± 4.4 kg for placebo (each p < 0.01, ANCOVA). The percentage of patients losing > 5% / >10% of initial body weight was significantly greater for all doses of cathine than for placebo (each p < 0.01, chi-square test). Heart rate increased dose-dependently (by 1.2 bpm under 16 mg, 5.8 bpm under 32 mg, and 6.2 bpm under 53.3 mg cathine), but no suspected unexpected serious adverse reactions were noted. The overall dropout rate was 24.9%, with the highest rate in the placebo group (42.3%). Conclusion: Cathine appears to be an effective weight-lowering agent for adjunct treatment of obesity, but additional clinical studies on its efficacy and safety are required.

© 2017 The Author(s) Published by S. Karger GmbH, Freiburg


References

  1. WHO: Obesity and overweight, Fact sheet no. 311, updated June 2016. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ (last accessed August 21, 2017).
  2. NCD Risk Factor Collaboration: Trends in adult body mass index in 200 countries from 1975 to 2014:a pooled analysis of 1598 population based measurement studies with 19.2 million participants. Lancet 2016;387:1377-1396.
  3. Caveney E, Caveney BJ, Somaratne R, Turner JR, Gourgiotis L. Pharmaceutical interventions for obesity: a public health perspective. Diabetes, Obes Metab 2011;13:490-497.
  4. Walter CP, Bleska BE, Dorsch MP: Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. J Clin Pharmacy Ther 2014;39:475-484.
  5. Toplak H, Woodward E, Yumuk V, Oppert JM, Halford JC, Frühbeck G: 2014 EASO position statement on the use of anti-obesity drugs. Obes Facts 2015;8:166-174.
  6. Hauner H. Orlistat; in Hofbauer KG, Keller U, Boss O (eds): ‘Pharmacotherapy of Obesity: Options and Alternatives.' Boca Raton, CRC Press, 2004, pp 219-244.
  7. Henness S, Perry CM: Orlistat: a review of its use in the management of obesity. Drugs 2006;66:1625-1656.
  8. Pi-Sunyer X, Astrup A, Fujioka K, et al: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.
  9. Kalix P: Pharmacological properties of the stimulant khat. Pharmacol Ther 1990;48:397-416.
  10. Balint EE, Falkay G, Balint GA: Khat - a controversial plant. Wien Klin Wochenschr 2009;121:604-614.
  11. Al-Motarreb A, Al-Habori M, Broadley KJ: Khat chewing, cardiovascular diseases and other internal medical problems: the current situation and directions for future research. J Ethnopharmacol 2010;132:540-54.
  12. Kelly JP: Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011;3:439-453.
  13. Szelenyi I, Bräuer H: Kontrollierte Prüfung von d-Nor-Pseudoephedrin auf Effektivität und Unschädlichkeit. Wien Med Wochenschr 1974;124:49-52.
  14. Spranger J, Dörken J: Kindliche Adipositas: Prüfung der Psychodynamik unter d-Norpseudoephedrin. Monatsschr Kinderheilk 1966;114:394-396.
  15. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K; Study Group SA; SAT Study: Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes 2004;112:201-207.
  16. Bjelland J, Dahl AA, Haug TT, et al: The validity of the Hospital Anxiety and Depression Score: an undated literature review. J Psychosom Res 2002;52:69-77.
  17. Riemser: Pharmacovigilance database of the Riemser Pharma GmbH.
  18. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM: Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes 2005;29:509-516.
  19. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al: Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-917.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: March 08, 2017
Accepted: June 07, 2017
Published online: September 06, 2017
Issue release date: August 2017

Number of Print Pages: 13
Number of Figures: 4
Number of Tables: 4

ISSN: 1662-4025 (Print)
eISSN: 1662-4033 (Online)

For additional information: https://www.karger.com/OFA


Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.